News
Science Raises $230M to Commercialize PRIMA Vision Implant
Science closed an oversubscribed $230M Series C, taking total raised to ~$490M, to commercialize PRIMA in Europe, expand trials into Stargardt and RP, and scale manufacturing and clinical ops in 2026.
March 6, 2026